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Direct detection of Streptococcus pneumoniae DNA in blood adds to culture results in the etiological diagnosis
of patients with community-acquired pneumonia (CAP). Quantification of the amount of DNA, the bacterial
DNA load (BDL), provides a measurement of DNAemia that may increase the understanding of the clinical
relevance of S. pneumoniae DNA in blood. We evaluated the S. pneumoniae BDL as a diagnostic tool in adult
patients with CAP. The BDL was determined in whole-blood samples collected simultaneously with blood for
culture from 45 adult patients with CAP. After DNA extraction, S. pneumoniae DNA was detected with specific
real-time PCR amplification, and the BDL was calculated with a standard curve. PCR and microbiological
results were compared, and the BDL was related to clinical and laboratory parameters. S. pneumoniae DNA was
detected in 10/13 patients with positive blood cultures and in 67% of patients with microbiologically confirmed
pneumococcal pneumonia. The positive predictive values of the receiver operating characteristic curves for the
BDLs for pneumococcal infection (100%) and pneumococcal bacteremia (69%) were higher than those for the
level of C-reactive protein (CRP; 43% and 23%, respectively) and the white blood cell count (WBC; 42% and
35%, respectively); the negative predictive values of these three parameters were in the same range (90 and
97%, respectively). The BDL was higher in patients presenting with systemic inflammatory response syn-
drome and in patients with bacteremia. Positive correlations were observed for the BDL with WBC, CRP level,
and length of stay. We conclude that the BDL supports the diagnosis of S. pneumoniae infection in patients with
CAP and provides a putative marker of the severity of disease.
Streptococcus pneumoniae is the most prevalent cause of
community-acquired pneumonia (CAP) in adults (1, 10). Iden-
tification of S. pneumoniae as a cause of CAP can be achieved
with Gram stain microscopy, culture of respiratory tract sam-
ples, blood culture, PCR, and antigen detection testing (26). A
positive blood culture result provides a definite diagnosis.
However, blood cultures have a low sensitivity for the confir-
mation of the pneumococcal etiology of CAP. This is due to
the low prevalence of bacteremia in CAP, especially in uncom-
plicated cases, and the use of antibiotics prior to drawing blood
samples for culture (11, 18, 32). In addition, blood cultures
usually require 1 or 2 days before results are available and thus
may have limited impact on the initial choice of empirical
antimicrobial treatment (6, 29). PCR and antigen detection
provide non-culture-based tools for the rapid identification of
S. pneumoniae in respiratory tract specimens, pleural aspirate
samples, and blood samples (7, 8, 13). These tests can add to
culture methods in the etiological diagnosis of patients with
CAP, particularly for patients who received antimicrobial
treatment prior to sampling for culture (13, 26, 33).
Several studies have evaluated the use of real-time PCR
assays for the detection of S. pneumoniae DNA in blood sam-
ples from patients suspected of infection with invasive pneu-
mococcal disease, with variable results (5, 14, 24, 31). These
studies all used blood culture as the reference standard. How-
ever, positive PCRs relate not only to bacteremia but also to
detection of DNA from nonviable bacteria, i.e., within phago-
cytes or due to the use of antibiotics. As such, it is understand-
able that most studies found cases with positive S. pneumoniae
DNAemia and negative blood cultures. In this study, we used
microbiologically documented S. pneumoniae infection as the
gold standard for evaluation of PCR results and hypothesized
that the bacterial DNA load (BDL) can be used to discriminate
between patients with invasive infection and those with local-
ized infection.
The magnitude of bacteremia, as based on quantitative
blood cultures, relates to the severity of S. pneumoniae infec-
tion (2). A high bacterial count in blood samples from children
with bacteremia is associated with an increased risk of devel-
opment of more-serious disease (27). Also, a shorter amount
of time needed to detect positivity for blood cultures, suppos-
edly reflecting a higher initial bacterial load, is associated with
higher severity of disease (20). This relation between bacterial
concentration and severity of disease may also hold true for the
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level of S. pneumoniae DNA in blood samples: the S. pneu-
moniae BDL was higher in human immunodeficiency virus-
infected children who died from invasive pneumococcal dis-
ease than in survivors (5).
In this study, we evaluated the S. pneumoniae BDL as a
putative diagnostic tool and clinical marker of infection in
adult patients with CAP.
MATERIALS AND METHODS
Collection of patient samples and data. This study was conducted during a
16-month period at the Scheper Hospital in Emmen, which serves a regional
function in the rural, northeast area of The Netherlands, and was approved by
the local Medical Ethical Committee. Participating departments included the
department of internal medicine, the emergency department, and the intensive
care unit. When blood was drawn for culture upon clinical indication from
patients admitted to these departments, a whole-blood sample was simulta-
neously and routinely collected and stored at 20°C. Retrospectively, the fol-
lowing inclusion criteria were used to select blood samples from these stored
blood samples for analysis of the S. pneumoniae BDL: samples from all adult
patients (18 years of age) who were admitted with CAP (as defined below) and
had blood samples drawn for culture and PCR within 24 h of admission.
Clinical and laboratory data, including C-reactive protein (CRP) values and
white blood cell counts (WBC), were collected retrospectively from patients’
charts and were included only if they had been determined within 12 h of the
time point of blood sampling for the BDL in order to obtain the best possible
analysis of the association among these variables.
Clinical definitions. CAP was defined as an acute respiratory illness associated
with at least two of the following symptoms plus the presence of an infiltrate on
a chest radiograph: cough, dyspnea, pleuritic chest pain, fever or hypothermia
(temperature of 36 or 38°C, respectively), and auscultatory findings of ab-
normal breath sounds and rales. Pneumonia was considered to be of pneumo-
coccal etiology when S. pneumoniae was isolated from a blood sample, pleural
fluid sample, or respiratory tract sample. Bacteremia was defined as the isolation
of S. pneumoniae from blood culture. The systemic inflammatory response syn-
drome (SIRS) was defined as described by Bone and colleagues (4). The pneu-
monia severity index (PSI) and CURB-65 score were used as described else-
where (9, 15). The SIRS criteria, PSI, and CURB-65 score are well-accepted
clinical measures of the severity of pneumonia infection.
Microbiological investigations. Blood samples were collected in blood culture
bottles (BacT/Alert FAN) for routine culture. After automatic detection of
growth, microorganisms were identified with standard microbiological tech-
niques. Gram stain microscopy and culture of sputum samples were performed
according to standard microbiological principles (25). Serological analysis for
Chlamydia pneumoniae (sandwich enzyme-linked immunosorbent assay; Medac,
Wedel, Germany) and Mycoplasma pneumoniae (Virotech enzyme immunoassay;
Genzyme Virotech, Ru¨sselsheim, Germany) and the urinary antigen test for
Legionella pneumophila (Binax NOW; Binax, Inc., Emergo Europe, The Hague,
The Netherlands) were done when indicated by the clinician.
Determination of the BDL. Blood samples for PCR were collected in 3 ml
EDTA tubes (Becton Dickinson). Prior to DNA isolation, 3,000 copies of pho-
cine herpesvirus 1 (PhHV-1) used as an extraction and inhibition control (equal
to 300 copies/PCR) were spiked with 200 l of blood (30). Blood samples were
treated to remove hemoglobin, as described elsewhere (21). DNA was then
extracted from the equivalent of 200 l of blood with the QIAamp DNA minikit
(Qiagen, Germany), according to the manufacturer’s instructions, and eluted in
100 l of elution buffer.
DNA amplification was done using a TaqMan 7000 system (Applied Biosys-
tems, Foster City, CA) with oligonucleotide primers and probes specific for S.
pneumoniae and PhHV-1 DNA (Table 1). The technical specificity of these
primers and probes was evaluated for a large number of S. pneumoniae-related
species, and no cross-reactions were observed. For each reaction, we used 20 l
of DNA in a total reaction volume of 50 l. The analytical sensitivity of this S.
pneumoniae PCR assay was less than 5 CFU equivalents/PCR, as determined by
a dilution series of S. pneumoniae (strain ATCC 6306) spiked with pooled,
culture-negative whole-blood samples.
PCR results were defined as positive when amplification signals were observed
and negative if such a signal was absent in the presence of an adequate ampli-
fication of the PhHV-1 internal control reaction. If a PhHV-1 control failed,
DNA from that sample was diluted 1:1 with phosphate-buffered saline and
amplified again. If the PhHV-1 amplification signal then was still insufficient, the
blood samples were retested. If the PhHV-1 control reactions failed twice, the
sample was considered inhibited.
The BDL was calculated with a standard curve of S. pneumoniae DNA, con-
sisting of four 10-fold dilutions of a stock solution of 5,000 CFU equivalents/PCR
(strain ATCC 6306). This standard curve was generated after isolation of DNA
from pooled, culture-negative blood samples spiked with the relevant amount of
bacteria. In case two blood samples had been obtained simultaneously from one
patient, the average BDL for these samples was computed. The detection limit
for the BDL in the blood samples was 5 CFU equivalents/PCR, which equals 125
CFU equivalents/ml blood.
Statistical analysis. Statistical analysis was performed with SPSS version 15.0
(SPPS Inc., Chicago, IL). Standard two-by-two tables were calculated for sensi-
tivity and specificity. Comparison of groups was performed using the Mann-
Whitney U test or Kruskal-Wallis test for continuous variables and the chi-
square test or Fisher’s exact test for categorical variables. Spearman rank
correlation (rs) was used to describe the relationship between continuous vari-
ables. Receiver operating characteristic (ROC) curves were designed and ana-
lyzed with MedCalc version 9.6.4.0 (MedCalc Software, Mariakerke, Belgium).
The positive predictive values (PPV) and negative predictive values (NPV) of the
ROC curves were calculated on the basis of an estimated disease prevalence of
25% for S. pneumoniae infection and 10% for pneumococcal bacteremia in
patients with CAP (3, 14, 17, 28). P values of 0.05 were considered to be
statistically significant.
RESULTS
Patient characteristics. Blood samples from 45 patients with
CAP, of whom 3 (7%) were admitted to the intensive care unit,
were included (Table 2). Twelve patients (27%) had taken
antibiotics within 48 h of admission. Microbiologically con-
firmed pneumococcal pneumonia was present in 18/45 (40%)
of patients, as demonstrated by positive cultures of blood (n 
13), sputum (n  10), and throat (n  1) samples. Six of the
thirteen patients with pneumococcal bacteremia also had a
positive culture of a sputum (n  5) or throat (n  1) sample;
the last patient presented with classical symptoms and a chest
X ray of lobar pneumonia. Nine out of forty-five patients with
TABLE 1. Sequences of oligonucleotide primers and probes used for real-time PCRa
Microorganism Gene target
Sequence (5–3)
Forward primer Reverse primer(s) Dye-labeled probe
S. pneumoniae lytA ACCGCTGGAGGAAGCACA GCCTGTAGCCATTTCGCCT AGACGGCAACTGGTACTc
AGCGATTTTCTTCCAGCCTGT
PhHV-1b gB polymerase GGGCGAATCACAGATTGAATC GCGGTTCCAAACGTACCAA CGCCACCATCTGGATd
a Abbreviations: lytA, autolysin A gene; FAM, 6-carboxyfluorescein; NFQ, nonfluorescent quencher; MGB, minor groove binding; gB, glycoprotein B; NED,
2,7,8-benzo-5-fluoro-2,4,7-trichloro-5-carboxyfluorescein.
b As published by van Doornum et al. (30). The probe was modified into a minor groove binding probe.
c Minor groove binding probe with 6-carboxyfluorescein label and nonfluorescent quencher.
d Minor groove binding probe with 2,7,8-benzo-5-fluoro-2,4,7-trichloro-5-carboxyfluorescein (NED) and fluorescent quencher.
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CAP (20%) had another presumed etiological diagnosis: six
patients had other bacteria isolated from sputum samples, in-
cluding Pseudomonas aeruginosa (n  3), Haemophilus influ-
enzae (n  2), Serratia marcescens (n  1), and Moraxella
catarrhalis (n  1), and one patient had pneumonia related to
urosepsis caused by Enterococcus species. Six patients were
evaluated for C. pneumoniae and M. pneumoniae infection, and
in nine cases, urinary antigen testing for L. pneumophila was
done. Two patients had C. pneumoniae infection, as suggested
by serological reaction, but no cases of M. pneumoniae or L.
pneumophila were identified. The microbiological etiology of
CAP remained unknown for 18 patients (40%).
PCR amplification results. PCR amplification results were
generated with blood samples from 44 patients with CAP; the
control reactions failed for both blood samples from one pa-
tient who was excluded from further analysis. PCR amplifica-
tion results generated from blood samples were positive for
12/18 (67%) of patients with pneumococcal pneumonia and for
10/13 (77%) of patients with S. pneumoniae bacteremia. Of the
five patients with nonbacteremic pneumococcal pneumonia,
two had positive PCR results. Both patients had received an-
tibiotics 48 h before admission, while no other patient with
pneumococcal pneumonia had received antibiotics prior to
sampling. PCR results for all blood samples from patients with
pneumonia of nonpneumococcal or unknown etiology were
negative, resulting in a PCR specificity of 100% for the S.
pneumoniae etiology of CAP.
BDL for prediction of S. pneumoniae infection. BDLs were
determined for 43/44 patients with PCR amplification signals.
Despite a positive amplification result, the BDL could not be
determined for one patient with bacteremic pneumococcal
pneumonia because of partial inhibition of PCR (a positive
amplification result but with an inadequate inhibition control
reaction); this patient was excluded from further quantitative
analysis. The median BDL was 325 CFU equivalents/ml
(range, 125 to 2,350 CFU equivalents/ml) for patients with
pneumococcal pneumonia and 125 CFU equivalents/ml for
those with pneumonia with another cause. ROC curves were
generated for the BDL, WBC, and CRP values for the predic-
tion of S. pneumoniae etiology of CAP and for the presence of
S. pneumoniae bacteremia (Table 3). No difference was ob-
served in the discriminative power for the BDL compared with
those for the CRP level (P  0.3) and the WBC (P  0.7) for
S. pneumoniae etiology and that for the BDL for prediction of
S. pneumoniae bacteremia (P of 0.6 compared to the CRP level
and the WBC). The PPV of the BDL for S. pneumoniae infec-
tion (100%) and for S. pneumoniae bacteremia (69%) were
higher than those of the WBC (42 and 35%, respectively) and
TABLE 2. Clinical characteristics of the study population
Characteristic
Value for patients with:
Pneumococcal
pneumonia
(n  18)
Nonpneumococcal
pneumonia
(n  27)
Gender (males/females) 12/6 17/10
Age (yr) 69 (24–84) 71 (32–85)
Length of hospitalization (days) 12 (1–60) 9 (2–19)
No. of mortalities 2 (11) 3 (11)
No. with COPD 8 (44) 12 (44)
No. with history of pneumonia
(5 yr)
5 (28) 6 (22)
No. with cough 16 (89) 21 (78)
No. with dyspnea 13 (72) 19 (70)
No. with chest pain 6 (33) 7 (26)
No. with cold chills reported 6 (33) 11 (41)
No. receiving antibiotic
treatment before admission
2 (11) 10 (37)
Body temp (°C) 39.1 (36.4–40.6) 39.0 (35.5–40.3)
Heart rate (beats/min) 109 (64–150) 100 (60–130)
Systolic blood pressure (mm Hg) 130 (90–170) 130 (80–195)
No. with abnormalities on
auscultation
17 (95) 19 (76)
No. with mental status alteration 4 (22) 3 (11)
No. with SIRS 17 (100) 17 (63)
PSI (class) 3 (1–4) 3 (1–5)
CURB-65 score 2 (0–3) 2 (0–5)
a Data are presented as numbers (percentages) for dichotomous variables and
as median values (ranges) for continuous variables. No significant statistical
difference was observed for clinical characteristics between patients with and
without a pneumococcal origin for CAP. COPD, chronic obstructive pulmonary
disease.
TABLE 3. ROC curve values for prediction of Streptococcus pneumoniae infection and bacteremia in patients with CAP
ROC curve parametera
Marker of infection values
BDL WBC CRP
S. pneumoniae infection
AUC (95% CI) 0.82 (0.68–0.92) 0.79 (0.63–0.90) 0.72 (0.56–0.85)
Optimal cutoff value 125 13.3 187
Sensitivity (%) 65 82 65
Specificity (%) 100 62 77
PPV (%) 100 42 43
NPV (%) 90 91 87
S. pneumoniae bacteremia
AUC (95% CI) 0.86 (0.72–0.95) 0.80 (0.65–0.91) 0.81 (0.66–0.91)
Optimal cutoff value 225 16.8 187
Sensitivity (%) 75 67 83
Specificity (%) 97 87 77
PPV (%) 69 35 23
NPV (%) 97 96 98
a The units of measurement for the optimal cutoff values: BDL, CFU equivalents/ml; WBC, number of cells  109/liter; CRP, mg/liter. 95% CI, 95% confidence
interval.
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the CRP level (43 and 23%, respectively); the NPV of these
parameters were in the same range (approximately 90 and 97%).
Association of the BDL with clinical and laboratory vari-
ables. The S. pneumoniae BDLs were higher in patients with S.
pneumoniae bacteremia compared to those in patients with
nonbacteremic pneumococcal pneumonia and with pneumonia
of another origin (Fig. 1). Presentation with SIRS upon admis-
sion was associated with a higher BDL (P  0.04). Positive
correlations were observed for the BDL with the CRP value
(rs  0.55; P  0.001) and with the WBC (rs  0.43; P  0.01).
In addition, a positive correlation was noted between the BDL
and the length of stay (rs  0.30; P  0.05). No other associ-
ations were observed between the BDL and the variables listed
in Table 2. In patients with S. pneumoniae pneumonia, the
BDL was associated with the length of stay (rs  0.49; P 
0.04), mental status alteration (P  0.04), and CRP level (rs 
0.66; P 0.001). Finally, there was a tendency for higher BDLs
to occur in patients with a PSI class higher than 2 (P  0.08).
DISCUSSION
In this study, we showed that the S. pneumoniae BDL in
blood samples is a diagnostic marker of pneumococcal infec-
tion and relates to the severity of disease in adult patients with
CAP. We performed a quantitative analysis of S. pneumoniae
DNA in blood samples, while previous studies have focused on
the diagnostic concordance of PCR (DNA positive or nega-
tive) with blood culture results (7, 14, 23, 24, 31). The intro-
duction of the BDL as a marker of infection enables clinical
prediction of S. pneumoniae infection and helps gain insight
into the clinical interpretation of a positive DNAemia. In our
study, 77% of patients with bacteremia had S. pneumoniae
DNA detected in whole-blood samples. This is a higher level of
sensitivity than that reported previously in adult CAP patients
(i.e., around 40%) and in patients with invasive pneumococcal
disease (69%), but it is lower than the level in a cohort of
patients with suspected meningitis and/or septicemia (92%) (7,
23, 24). In another study, S. pneumoniae DNA was detected in
all three patients with bacteremia in a cohort of 28 patients
with CAP and in 3/5 patients with a positive urinary antigen
test and negative blood culture (14). In our study, S. pneu-
moniae DNA was detected in 67% of patients with microbio-
logically confirmed pneumococcal pneumonia, which is higher
than the level reported by Lorente et al. (55%) (16). In that
study, a higher rate of PCR-positive results was observed in
patients with bacteremia than in patients with nonbacteremic
pneumonia. We had a relatively high proportion of CAP pa-
tients with bacteremia, which may have introduced some bias.
This was partially overcome by using a corrected disease prev-
alence value in the calculation of the PPV and NPV of the
ROC curves. The specificity of S. pneumoniae DNA in blood
was 100% for pneumococcal etiology. As such, a positive S.
pneumoniae DNAemia value in blood samples excluded other
causes of CAP in our setting.
The BDL in our study was in concordance with the range of
BDLs described in another study of adult patients with CAP
and was higher than those reported for Malawian children with
pneumonia (5, 14). The BDL had a good discriminative value
for the S. pneumoniae origin of infection and for the presence
of bacteremia. The values for the area under the curve (AUC)
of the ROC curves for the BDL (0.82 and 0.86 during infection
and during bacteremia, respectively) were higher than those of
the WBC and CRP level. This was not statistically different,
which might be due to our small study population and possibly
relatively high discriminative values of the CRP level and the
WBC in our study: a recent study by Mu¨ller et al. describes
AUC values of 0.68 and 0.71 for the WBC and the CRP level,
respectively, for the prediction of bacteremia (33/42 of pneu-
mococcal origin) in 373 patients with CAP (17). The PPV of
the BDL for the prediction of S. pneumoniae infection (100%)
in our study were much higher than those of the WBC (42%)
and the CRP level (48%), while the NPV were equally high for
all three parameters. As such, the BDL is likely to add to the
CRP level and the WBC in confirmation of the pneumococcal
origin of pneumonia. This prompts treatment for pneumococ-
cal infection regardless of the CRP level and the WBC results
if the BDL is above the defined cutoff value. In this respect, the
BDL also improves upon blood culture, because the BDL can
be available within a few hours compared to 1 to 2 days for
blood culture.
We observed a relationship between the BDL and several
clinical and laboratory markers of the severity of disease, as
follows: SIRS, mental status alteration upon admission, and
the level of CRP. Also, the BDL tended to be higher in pa-
tients with invasive disease and in those with a PSI class higher
than 2. This confirms earlier findings where a higher S. pneu-
moniae BDL in children with meningitis was reportedly com-
pared to those in children with pneumonia, and the BDL in
nonsurvivors was compared to that in survivors (5). In addi-
tion, another study reported an association of the Neisseria
meningitidis BDL with more-severe disease in children with
meningitis (12). Altogether, these data suggest a role for the
testing of BDL in identification of patients with high risk for
FIG. 1. Distribution of the BDL in relation to the type of pneumo-
nia. The P value reflects the Kruskal-Wallis analysis of variance among
groups. The dashed line indicates the lower detection limit. equiv,
equivalents.
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severe or complicated disease. Possibly, the S. pneumoniae
BDL can be used to support the choice between hospital ad-
mission and outpatient treatment of CAP patients. As such, a
large prospective study is highly warranted to define the clin-
ical application and benefit of the S. pneumoniae BDL in the
treatment of patients with CAP. Monitoring of the course of
the BDL during treatment is another interesting potential ap-
plication (19, 21). Like the CRP level, the course of the BDL
might be indicative of its response to treatment or the devel-
opment of complicated disease (22). Although the kinetics of
microbial DNA in blood are largely unknown, monitoring of
the BDL under treatment certainly warrants further study.
Important determinants for the potential application and clin-
ical utility of the BDL will be the performance, turnaround
time of the assay, logistics, organization of the laboratory ser-
vices, and the costs.
In conclusion, a positive BDL value supports the diagnosis
of S. pneumoniae infection in patients with CAP and should
prompt targeted treatment, while a negative BDL value does
not exclude S. pneumoniae infection. The BDL provides a
putative quantitative marker for the severity of disease.
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